Zai Lab Limited American Depositary Shares (ZLAB) Stock
Key stats
- Market cap
- $3.27B
- Price / Earnings ratio
- -15.0x
- EPS (TTM)
- -$1.90
- Volume
- Loading
- 52-week high
- $29.02
- 52-week low
- $15.96
Source: third-party data provider, as of November 13, 2026
Compare with ZLAB
Recent news

Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
ZLAB

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
ZLAB

Zai Lab Announces $250 Million Private Placement
Zai Lab Announces $250 Million Private Placement
ZLAB

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
ZLAB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 60.79
- MACD 12/26/9
- 0.31
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.51
- SMA 50
- $24.67
- Price above SMA 50
- EMA 50
- $24.10
- Price above EMA 50
- SMA 200
- $21.22
- Price above SMA 200
- EMA 200
- $21.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.20 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study
ZLAB

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
ZLAB

Zai Lab Announces $250 Million Private Placement
Zai Lab Announces $250 Million Private Placement
ZLAB

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
ZLAB

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
ZLAB

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
ZLAB

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
ZLAB

Zai Lab Q2 Earnings Call Highlights
Zai Lab Q2 Earnings Call Highlights
ZLAB

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
ZLAB

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
ZLAB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zai Lab Limited American Depositary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1966 |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer | 1968 |
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D | 1964 |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 1964 |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations | — |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.79
- MACD 12/26/9
- 0.31
- EMA 9 of MACD
- -0.20
- MACD histogram
- 0.51
- SMA 50
- $24.67
- Price above SMA 50
- EMA 50
- $24.10
- Price above EMA 50
- SMA 200
- $21.22
- Price above SMA 200
- EMA 200
- $21.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -19.4 | -11.8 | ||||||||||
| 2022 | -22.9 | +2.1 | -16.3 | -12.1 | -26.4 | +17.6 | +5.2 | +18.9 | -26.1 | -35.0 | +54.1 | -15.1 |
| 2023 | +36.6 | -12.6 | -17.6 | +3.0 | -6.6 | -16.0 | +4.5 | -13.2 | -6.9 | +5.7 | +10.3 | -0.6 |
| 2024 | -17.2 | -6.8 | -24.1 | -5.5 | +11.8 | -3.7 | +10.1 | +8.1 | +24.8 | +21.6 | -5.3 | -10.3 |
| 2025 | +9.6 | +26.5 | +13.9 | -15.0 | -3.2 | +12.1 | +7.5 | -10.1 | +1.6 | -24.1 | -23.7 | -11.3 |
| 2026 | -4.2 | +17.9 | +2.1 | +6.4 | -17.9 | +11.2 | -4.6 | +40.0 | +4.1 | -13.5 | +21.9 |



